Red blood cell nitric oxide synthase activation is increased in patients with sickle cell hemoglobin C disease

low number of patients in the DNR90 group leads to low statistical power hiding a potential difference between the two groups. However, hazard ratio in the multivariate model (0.91 for RFS and 0.84 for OS) do not support a dramatic influence of DNR dose in our series. Moreover, improvements of AML therapy results over time might confound the results of historical control comparison as previously shown [12,13], but in our analysis, this would have favor the DNR90 group. Although these limitations, our results are important to give the basis of a potential prospective comparison of these regimens with the objectives of confirming our retrospective data but more importantly to try to define subgroups of patients for which dose intensification may be beneficial.

[1]  K. Charlot,et al.  High red blood cell nitric oxide synthase activation is not associated with improved vascular function and red blood cell deformability in sickle cell anaemia , 2015, British journal of haematology.

[2]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[3]  E. Estey,et al.  Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson , 2014, Leukemia.

[4]  C. Récher,et al.  Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia , 2014, Haematologica.

[5]  M. Thevis,et al.  RBC-NOS-Dependent S-Nitrosylation of Cytoskeletal Proteins Improves RBC Deformability , 2013, PloS one.

[6]  J. Esteve,et al.  Impact of FLT3 ITD/NPM1 mutation status in adult patients with acute myelocytic leukemia autografted in first remission , 2013, Haematologica.

[7]  L. Créancier,et al.  Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience , 2011, Oncotarget.

[8]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Connes,et al.  Effects of oxidative stress on red blood cell rheology in sickle cell patients , 2014, British journal of haematology.

[10]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[11]  M. Béné,et al.  Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group , 2014, Haematologica.

[12]  A. Burnett.  Treatment of acute myeloid leukemia: are we making progress? , 2012, Hematology. American Society of Hematology. Education Program.

[13]  M. Patnaik,et al.  Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.

[14]  L. Bullinger,et al.  The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. , 2013, Blood.

[15]  J. Detterich,et al.  Nitric oxide, vasodilation and the red blood cell. , 2014, Biorheology.

[16]  Thomas Lauer,et al.  Red blood cells express a functional endothelial nitric oxide synthase. , 2006, Blood.

[17]  P. Connes,et al.  Impaired blood rheology plays a role in the chronic disorders associated with sickle cell-hemoglobin C disease , 2014, Haematologica.

[18]  M. Béné,et al.  Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia , 2014, Leukemia.

[19]  H. Döhner,et al.  High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.